Brazilian pharma co Eurofarma to source power from 211.5-MW wind project

Brazilian pharmaceutical company Eurofarma has signed a contract with local energy company Omega Energia SA (BVMF:MEGA3) to procure electricity from the 211.5-MW Assurua 4 wind project.

The power supply to Eurofarma is scheduled to commence in 2024, the pharma company said.

Subscribe for Renewables Now's Corporate PPA Newsletter here for free!

The agreement ensures that Eurofarma's energy needs are met with renewable power and 260,000 tonnes of carbon dioxide (CO2) emissions in the atmosphere will be offset by 2038.

Eurofarma and Omega's deal will be finalised once the usual precedent conditions are met, such as the approval by the Brazilian antitrust regulator CADE and other financial institutions.

Omega unveiled the acquisition of the Assurua 4 and the 243.6-MW Assurua 5 projects in March 2022. The two wind farms are scheduled to become fully operational in 2023. With the deal, the energy supplier took full control of the gigawatt-scale Assurua renewable energy complex.